The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discu ...

Earlier this month, Sarepta Therapeutics, which is responsible for commercializing Elevidys in the US while Roche markets Elevidys in other countries, reported preliminary financial results and ...

Objective indices of functional capacity in patients with diabetic cardiomyopathy and stage B heart failure (HF) have not been comprehensively defined. We sought to characterize the cardiopulmonary ...

In 2019, Roche entered into a global collaboration agreement with Sarepta Therapeutics, Inc. to commercialise Elevidys in territories outside the US. Study 101 (NCT03375164), a phase I/II study ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene moxeparvovec) in children with the rare muscle-wasting disorder Duchenne ...

Under a collaboration agreement between Roche and Sarepta signed in 2019, Sarepta is responsible for the regulatory approval, commercialization, and manufacturing of Elevidys in the United States, ...

Sarepta developed the therapy and markets it in the U.S., while Roche markets it outside the U.S. The one-time therapy is fully approved for DMD patients in the U.S., ages 4 and older, who can walk ...